Financial Performance - The company reported total revenue of 232 million yuan, ranking 98th among disclosed peers [1] - The net profit attributable to shareholders was -54.08 million yuan, ranking 113th among disclosed peers [1] - The net cash inflow from operating activities was 66.35 million yuan [1] Financial Ratios - The latest debt-to-asset ratio is 41.72%, ranking 83rd among disclosed peers, an increase of 3.41 percentage points compared to the same period last year [3] - The latest gross profit margin is 53.74%, a decrease of 2.87 percentage points compared to the same period last year [3] - The latest return on equity (ROE) is -4.98%, ranking 113th among disclosed peers [3] Earnings and Turnover - The diluted earnings per share is -0.12 yuan, ranking 109th among disclosed peers [4] - The latest total asset turnover ratio is 0.12 times, ranking 103rd among disclosed peers [4] - The latest inventory turnover ratio is 0.61 times, ranking 103rd among disclosed peers [4] Shareholder Information - The number of shareholders is 31,900, with the top ten shareholders holding 164 million shares, accounting for 35.97% of the total share capital [4] - The largest shareholder is Hainan Hongshi Investment Co., Ltd., holding 27.25% of the shares [4]
康芝药业(300086.SZ):2025年中报净利润为-5408.17万元